Molecular Formula：
C82H103ClN18O16
Relative Molecular Mass：
1632.28 g/mol
CAS-Number：
214766-78-6 (net)
Long-term Storage：
-20 ± 15°C
Synonym：
FE200486
Sequence：
Ac-D-2-Nal-D-4-Cpa-D-3-Pal-Ser-4-amino-Phe(L-hydroorotyl)-4-ureido-
D-Phe-Leu-Lys(isopropyl)-Pro-D-Ala-NH2 acetate salt
Fields of Application：
Advanced hormone-dependent prostate carcinoma
Active Substance：
Degarelix Acetate is an LHRH (GnRH) receptor antagonist, indicated for patients with advanced prostate cancer. Degarelix reversibly and dose-dependently suppresses gonadotropin and sex steroid levels by inhibiting the binding of endogenous LHRH to its receptors.
Degarelix showed to be at least as effective as leuprolide in sustaining levels of testosterone that are equivalent to or lower than that seen with castration.
Main product
Peptide APIs: Oxytocin Acetate,Vasopressin Acetate,Desmopressin Acetate,Terlipressin acetate, Caspofungin acetate, Micafungin sodium, Eptifibatide acetate, Bivalirudin TFA, Deslorelin Acetate,Glucagon Acetate,Histrelin Acetate,Liraglutide Acetate,Linaclotide Aceteate ,Degarelix Acetate,Buserelin Acetate,Cetrorelix Acetate,Goserelin Acetate.
Cosmetic peptide: Argireline Acetate, Metrixyl Acetate,Snap-8,.....
The process of these products is very mature and stable which let us have the ability to provide you with prompt response, better price and speedy delivery. And help you in selecting the right protection for your application.
Company Profile
Company: Shenzhen JYMed Technology Co., Ltd
Found in 2009, our peptide plant is located in Nanjing, Jiangsu province and it has set up a facility of 30,000 square meters in compliance with cGMP guideline. The manufacture facility has been audited and inspected by both domestic and international clients.
Contact
June Kang
Email: june@jymedtech.com
Tel: 86-0755-86350931
QQ: 821653780
健元醫(yī)藥（深圳市健元醫(yī)藥科技有限公司，英文名JYMed Peptide）成立于2009年，是一家專注于多肽產(chǎn)品研發(fā)、生產(chǎn)及銷售的國家級(jí)高新技術(shù)企業(yè)，現(xiàn)為上市公司四川和諧雙馬股份有限公司（股票代碼：000935）的控股子公司。
公司業(yè)務(wù)涵蓋多肽原料藥、CDMO、美容肽及定制合成四大板塊。作為國內(nèi)化學(xué)合成多肽領(lǐng)域規(guī)模領(lǐng)先的企業(yè)之一，健元醫(yī)藥在深圳坪山和湖北咸寧設(shè)有兩大生產(chǎn)基地，預(yù)計(jì)2026年下半年多肽原料藥年產(chǎn)能將突破10噸級(jí)規(guī)模。
公司產(chǎn)品線豐富，核心品種包括司美格魯肽、利拉魯肽等20余種多肽原料藥，其中10多個(gè)品種已在美國FDA完成DMF備案。公司建有超過7000平方米的研發(fā)中心，擁有130人以上的資深研發(fā)團(tuán)隊(duì)。憑借卓越的質(zhì)量體系，生產(chǎn)基地已2次通過美國FDA現(xiàn)場檢查。
健元醫(yī)藥提供從多肽藥物發(fā)現(xiàn)到商業(yè)化生產(chǎn)上市的全流程端到端CDMO服務(wù)，具備從毫克級(jí)到噸級(jí)API的生產(chǎn)能力。迄今已成功服務(wù)超過3000家CRO客戶、50多家CDMO客戶，并支持了20多個(gè)IND項(xiàng)目。